Navigation Links
Two New Studies in the British Medical Journal Find That Bayer's Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot
Date:4/22/2011

PHILADELPHIA, April 22, 2011 /PRNewswire-USNewswire/ -- The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto:

According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone (DSRP), carry up to triple the risk of serious blood clots (known as venous thromboembolism) over traditional pills containing the progestin levonorgestrel (LNG).

Approximately 2,000 lawsuits have been filed in Pennsylvania before Philadelphia Court of Common Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex Litigation Center.  Another 4,000 lawsuits are pending in federal court before the Judge David R. Herndon, who is overseeing the federal multidistrict litigation (MDL).  The lawsuits allege that Yaz and Yasmin have risks beyond those of traditional birth control pills and that Bayer over-promoted the drug without disclosing the higher risks. Bayer was warned by the Food and Drug Administration (FDA), in the fall of 2008, that Bayer's television advertisements were misleading and did not disclose the additional risks.

The findings of the new studies provide additional evidence that the older oral contraceptives "appear to be a safer choice with regard to venous thromboembolism than preparations containing drospirenone," says Dr. Susan Jick of Boston University's School of Medicine, who led the research team.

Judge Moss appointed three Pennsylvania lawyers as Liaison Counsel for the plaintiffs, including Michael M. Weinkowitz of Levin, Fishbein, Sedran & Berman, Philadelphia, Daniel N. Gallucci of RodaNast, P.C., Lancaster, and Rosemary Pinto of Feldman & Pinto, Philadelphia.  Dianne M. Nast, RodaNast, P.C. was appointed Pennsylvania Federal-State Liaison Counsel by the Honorable David Herndon.


'/>"/>
SOURCE RodaNast, P.C.; Levin, Fishbein, Sedran & Berman; Feldman & Pinto
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions
4. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
5. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
6. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
7. New Studies Show Clinical Advantages of Masimo Noninvasive Hemoglobin, PVI, and Perfusion Index in Critically-ill Patients
8. BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
9. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
10. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
11. Women Get Short Shrift in Many Heart Device Studies, Despite Requirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):